SOX18 and hepatocellular carcinoma: Results showed that BLU9931 treatment remarkably abrogates the SOX18-induced invasion and metastasis of HCC, suggesting that SOX18 is a biomarker for identifying HCC patients who benefit from FGFR4 inhibitor treatment [134].